Business Context and Reporting Period
This Form 8-K Current Report was filed by Silexion Therapeutics Corp on November 22, 2024. The registrant is a Cayman Islands corporation with principal executive offices in Ramat-Gan, Israel. The filing addresses critical compliance deficiencies with Nasdaq Listing Rules and announces a corporate action to address market value concerns.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status and capital structure adjustments.
Material Changes and Compliance Deficiencies
The Company received three deficiency letters from the Nasdaq Listing Qualifications Department between November 19 and November 20, 2024:
- Market Value of Listed Securities (MVLS): Non-compliance with Rule 5450(b)(2)(A) due to MVLS closing below $50,000,000 for 30 consecutive business days.
- Market Value of Publicly Held Shares (MVPHS): Non-compliance with Rule 5450(b)(2)(C) due to MVPHS falling below $15,000,000 for 30 consecutive business days.
- Audit Committee Composition: Non-compliance with Rule 5605(c)(2)(A) due to having only two members instead of the required three, following the resignation of Ilan Shiloah on September 16, 2024.
For the market value deficiencies, the Company has a 180-day cure period ending May 19, 2025. Failure to comply may result in delisting, subject to appeal rights.
Guidance, Outlook, and Corporate Actions
Reverse Share Split: To address market value deficiencies, the Company announced a prospective 1-for-9 reverse share split.
- Effective Date: After market close on November 27, 2024.
- Trading Resumption: November 29, 2024, on a reverse split-adjusted basis.
- Par Value Adjustment: Increases from $0.0001 to $0.0009 per share.
- Fractional Shares: Will be rounded up to the nearest whole number; no fractional shares issued.
- Ticker Symbol: Remains "SLXN".
Management Strategy: The Company intends to monitor market value and may consider transferring its listing to the Nasdaq Capital Market if necessary. It is actively seeking a qualified independent candidate to fill the audit committee vacancy before the cure period expires.
Investor Verification Checklist
- Verify the successful implementation of the 1-for-9 reverse share split on November 29, 2024.
- Monitor the Company's Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS) to ensure they meet the $50M and $15M thresholds, respectively, for 10 consecutive business days before May 19, 2025.
- Confirm the appointment of a new independent director to the audit committee to resolve the governance deficiency.
- Review any future filings regarding potential transfer to the Nasdaq Capital Market or appeals to a Nasdaq hearings panel.